Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
ERASthis companyErasca, Inc.	$15.04	-8.45×	3.24×	0×	-8.47×	-99.3%	0.0%	0.0%	0.0%	-38.3%	-35.3%	-9.1%	0.14×	0.22×	0×	10.04×	0.0%	1	35.36	1	C-
AVBPArriVent BioPharma, Inc.	$13.98	-4.66×	2.52×	0×	-4.38×	-92.2%	0.0%	0.0%	0.0%	-54.1%	-57.8%	-20.8%	0×	0.27×	0×	12.83×	0.0%	2	12.15	2	C+
CRISCuris, Inc.	$0.75	-1.7×	2.38×	1.38×	-1.83×	-1429.1%	99.5%	-348.4%	-80.3%	-138.8%	-464.7%	-209.4%	0.3×	0.66×	-15.06×	0.49×	0.0%	0	-98.45	1	C-
IDYAIDEAYA Biosciences, Inc.	$31.52	-27.01×	2.99×	13.99×	-19.22×	-438.0%	-43.9%	-72.8%	-52.0%	-11.1%	-15.2%	-2.4%	0.03×	0.55×	0×	11.34×	0.0%	1	14.74	2	C
KURAKura Oncology, Inc.	$7.63	-3.27×	5.23×	13.5×	-2.84×	72.0%	99.9%	-449.9%	-412.9%	-160.0%	-48.8%	-7.8%	0.12×	0.47×	-200.81×	6.06×	0.0%	3	-2.79	2	C
NUVBNuvation Bio Inc.	$4.27	-14.93×	10.01×	48.65×	-15.36×	-33.1%	86.6%	-338.7%	-325.3%	-66.9%	-41.0%	-5.7%	0.03×	0.81×	-15.57×	6.95×	0.0%	3	0.52	1	C-
Peer median	—	-4.66×	2.99×	13.5×	-4.38×	-92.2%	86.6%	-338.7%	-80.3%	-66.9%	-48.8%	-7.8%	0.03×	0.55×	-15.06×	6.95×	0.0%	2	0.52	2	—